UK scientists say they have found cancer driver in junk DNA
July 21, 2022Business Services
Scientists in the UK think they have understood the mechanism behind junk DNA, which is implicated in cancer. Junk DNA …
Strategic alliance for treatment of glaucoma
July 21, 2022Business Services
AbbVie and iSTAR Medical SA have announced a strategic transaction to further develop and commercialise iSTAR Medical’s MINIject® device. The …
First disease-modifying treatment for AADC deficiency
July 21, 2022Business Services
The European Commission (EC) has granted a marketing authorisation for Upstaza™ (eladocagene exuparvovec), the world’s first disease-modifying treatment for aromatic …
Transformational therapy cures bleeding disorder haemophilia B
July 21, 2022Business Services
Researchers have found that a single injection of a new gene therapy, called FLT180a, removed the need for people to …
Depression may not be caused by chemical imbalance
July 20, 2022Research and Development
A major review has found “no clear evidence” that low serotonin levels are responsible for depression. Reviewing existing studies, researchers …
COVID-19 boosters to be offered to all over 50s this autumn
July 20, 2022Research and Development
All those aged 50 and over will be offered a COVID-19 booster vaccine this autumn, to top up their immunity …
Potential shortage of 140,000 nurses in NHS England by 2030
July 20, 2022Research and Development
According to new analysis, the NHS in England could face a shortfall of almost 40,000 nurses by 2024, and under …
TSB and CR Pharma partner for COVID-19 antibody therapy in China
July 20, 2022Research and Development
TSB Therapeutics has entered a collaboration with China Resources Pharmaceutical Commercial Group (CR Pharma) for the commercialisation of an antibody …
Brain cancer treatment receives Orphan Drug Designation
July 19, 2022Manufacturing and Production
The FDA has granted an Orphan Drug Designation for DSP-0390, an investigational emopamil-binding protein (EBP) inhibitor for the treatment of …
MIT research demonstrates potential of self-boosting vaccines
July 19, 2022Manufacturing and Production
In a new study, MIT researchers describe the analysis of a release mechanism from biodegradable core-shell microparticles.Through understanding how and …
New reforms aim for better NHS dental service access
July 19, 2022Manufacturing and Production
Patients across the country will benefit from improved access to dental care under changes announced by NHS England, the organisation …
WHO to assist Ghana following confirmed Marburg cases
July 19, 2022Manufacturing and Production
WHO has announced that in the coming days it will deploy a team of experts to assist Ghana in tackling …
FDA approval for neurostimulation device to treat diabetic neuropathic pain
July 15, 2022Medical Communications
DyAnsys has received FDA approval for its First Relief device, a wearable device monitoring pulses of a low-level electrical current …
Step strategy effective in treating diabetic eye disease
July 15, 2022Medical Communications
An NIH-funded clinical from the DRCR Retina Network suggests that a specific step strategy for patients with diabetic macular edema …
FDA approves new treatment for rare tumour
July 15, 2022Medical Communications
The FDA has approved crizotinib for adult and paediatric patients aged 1 year and older with unresectable, recurrent, or refractory …
First immunotherapy for untreated, unresectable malignant pleural mesothelioma recommended by NICE
July 14, 2022Business Services
Bristol Myers Squibb (BMS) has announced that the NICE Final Appraisal Document (FAD) recommending the combination of nivolumab plus ipilimumab …
Trodelvy recommended in England for metastatic triple negative breast cancer
July 14, 2022Business Services
Gilead Sciences has announced the NICE recommendation of Trodelvy (sacituzumab govitecan) for use on the NHS in England, as an …
Nucleai partners with Sirona Dx for AI-driven discovery of biomarkers in solid tumours
July 14, 2022Business Services
Nuclei and Sirona Dx have announced a collaboration to advance the discovery of novel spatial biomarkers in solid tumours.The partnership …
Gene editing potential treatment for hereditary killer
July 13, 2022Research and Development
Verve therapeutics has dosed the first patient win its heart-1 clinical trial, studying the safety and efficacy of its in …
FDA accepts Byondis’ Biologics License Application for breast cancer treatment
July 13, 2022Research and Development
The FDA has accepted Byondis’ submission of a Biologics License Application (BLA) for [vic-] trastuzumab duocarmazine (SYD985) in patients with …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
